Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Status:
Recruiting
Trial end date:
2030-12-31
Target enrollment:
Participant gender:
Summary
This trial studies the side effects of enasidenib and to see how well it works in treating
patients with acute myeloid leukemia that has come back after treatment (relapsed) or has
been difficult to treat with chemotherapy (refractory). Patients must also have a specific
genetic change, also called a mutation, in a protein called IDH2. Enasidenib may stop the
growth of cancer cells by blocking the mutated IDH2 protein, which is needed for cell growth.